Melbourne-founded genomics company myDNA is joining the SPAC rush as it mulls a US-listing that could catapult it to a $US1 billion ($1.3 billion) valuation.
Not bad for a company that just a year ago was valued around $US200 million.
Loading...
Carrie LaFrenz is a senior journalist covering retail/consumer goods. She previously covered healthcare/biotech. Carrie has won multiple awards for her journalism including financial journalist of the year from The National Press Club. Connect with Carrie on Twitter. Email Carrie at carrie.lafrenz@afr.com
